ZURICH, April 30 (Reuters) – The World Health Organization has identified Moderna’s COVID-19 vaccine for emergency use, the agency said on Friday the fifth it will gain status to expedite the country’s approval of fires.
“The objective is to make drugs, vaccines and diagnoses available as quickly as possible to address emergency problems,” the WHO said in a statement.
Mariangela Simao, WHO assistant chief executive officer, said on Friday it was important to have more vaccines due to problems with other vaccine supply, including from India, the primary source of vaccines for the global COVAX vaccine sharing program, India. Restricted exports due to infection crisis
Moderna announced plans to expand its production network this week to increase production capacity to 3 billion doses by 2022.
The WHO Strategic Immunization (SAGE) group in January recommended Moderna vaccine for all age groups 18 and over.
German partner Pfizer and BionTech, mRNA vaccines such as Moderna, are the first vaccines to receive the WHO emergency use list in the last hours of 2020.
Since then, the WHO has increased the vaccine from Astrazeneca-SK Bio, Serum Institute of India, and Johnson & Johnson Vaccine are listed.
The Geneva-based health organization is still considering the COVID-19 vaccine from Sinopharm and Sinovac after further investigation, with a decision made at the end of next week.
(Reporting by John Miller, editing by Grant McCool)